arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Corbus Pharmaceuticals Holdings, Inc.

CRBP
$10.16 ▲ +0.45 (+4.63%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
53 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Corbus Pharmaceuticals Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $190.1M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -15.2%
FCF / Share $-1.37
Trailing P/E
Price / Book 1.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

53-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-22.97M
↓ -35.3%
FCF / Share Free cash flow per share
$-1.37
↓ -1.6%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
16
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 53 quarters